Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says
Executive Summary
Preliminary study results suggest policy tweaks may not be necessary, even as an oncology orphan product rush appears to be coming.
You may also be interested in...
Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure
Drug sponsors tell US GAO that orphan incentives don't draw them to the space, and several stakeholders say high prices and scientific discovery are the reason for the sector's growth.
Orphan Designations For Pediatric Subgroups Of Common Diseases To End
US FDA's draft guidance closes loophole where sponsors could obtain an orphan designation for a pediatric subset and then be exempt from requirements to conduct pediatric studies.
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.